Table 1 The characteristics of included studies
Study | Year | No. of patients | Patients | Intervention | Comparison | Outcome |
|---|---|---|---|---|---|---|
Malay | 1999 | 10 | Septic shock | Vasopressin 0.04 U/min | NE | 24 h |
Albanese | 2005 | 20 | Septic shock | Terlipressin: one bolus of 1 mg and a second bolus of 1 mg was given if the MAP < 65 mmHg after 20 mins | NE was started at a dose of 0.3 μg/kg/min, followed by 0.3 μg/kg/min increments at 4-min intervals to raise MAP to 65 to 75 mmHg | Hospital |
Lauzier | 2006 | 23 | Septic shock | Arginine-vasopressin 0.04–0.20 U/min | NE 0.1–2.8 μg/kg/min | ICU |
Russell | 2008 | 799 | Septic shock | Vasopressin 0.01–0.03 U/min or at clinician’s discretion | NE 5 to 15 mg/min or at clinician’s discretion | 90 days |
Acevedo | 2009 | 24 | Septic shock and cirrhosis | Terlipressin 1–2 mg/4 h plus alpha-adrenergic drugs | Alpha-adrenergic drugs alone | Hospital |
Morelli | 2009 | 45 | Septic shock | Terlipressin 1.3 μg/kg/h Vasopressin 0.03 U/min | NE 15 μg/min | ICU |
Han | 2012 | 139 | Septic shock | Pituitrin 1.0–2.5 U/h | Dopamine or NE 2–20 μg/kg/h | 28 days |
Svoboda | 2012 | 30 | Septic shock | Terlipressin 4 mg/24 h for 72 h plus open-label norepinephrine | NE > 0.6 μg/kg/min for more than 24 h | 28 days |
Fonseca Ruiz | 2013 | 30 | Septic shock | Vasopressin 0.01–0.04 U/min plus NE | NE | 28 days |
Hua | 2013 | 32 | Septic shock patients with ARDS | Terlipressin 1.3 mg/kg/h | Dopamine < 20 mg/kg/min | 28 days |
Oliveira | 2014 | 387 | Septic shock | Vasopressin 0.01–0.03 U/min with low doses of norepinephrine | NE 0.05–2.0 μg/kg/min | 28 days |
Barzegar | 2016 | 30 | Septic shock | Vasopressin 0.03 μg/min plus NE | NE: infusion adjusted to MAP ≥ 65 mmHg | 28 days |
Choudhury | 2016 | 84 | Cirrhotics with septic shock | Terlipressin 2–8 mg over 24 h | NE 7.5–60 μg/min | 28 days |
Clem | 2016 | 82 | Septic shock | Vasopressin 0.04 U/min plus NE with 0.05–0.5 μg/kg/min | NE 0.05 to 0.5 μg/kg/min | 28 days |
Gordon | 2016 | 408 | Septic shock | Vasopressin: titrated up to 0.06 U/min to maintain the MAP 65 to 75 mmHg | NE: titrated up to 12 μg/min to maintain the MAP 65 to 75 mmHg | 28 days |
Capoletto | 2017 | 250 | Septic shock and cancer | Vasopressin | NE | 90 days |
Chen | 2017 | 57 | Septic shock patients with ARDS | Terlipressin 0.01–0.04 U/min to maintain MAP between 65 and 75 mmHg, if necessary plus NE | NE > 1 μg/min to maintain MAP between 65 and 75 mmHg | 28 days |
Prakash | 2017 | 184 | Cirrhosis with septic shock. | Terlipressin 2 mg/24 h and 3.75–30 μg/min of NE as needed to maintain MAP > 65 mmHg | NE 7.5–60 μg/min | 30 days |
Russell | 2017 | 48 | Septic shock | Selepressin 1.25, 2.5, and 3.75 ng/kg/min until shock resolution or a maximum of 7 days | Placebo | 28 days |
Liu | 2018 | 535 | Septic shock | Terlipressin 20–160 μg/h | NE 4–30 μg/min | 28 days |